EMBRAER (EMBR3) Main Indicators
Basic Data - EMBR3
| Company | EMBRAER |
| Corporate Name | EMBRAER S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Projeto. desenvolvimento. fabricação. comercialização de aeronaves e sistemas e fornecimento de suporte e serviços de pós-venda. |
| Share | EMBR3 |
| Quote Date | 11/19/2024 |
| Share Type | ON |
| Last Closing | R$ 54.44 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 502.33 M |
| Last Statement | ITR - 09/30/2024 |
| Sector | Bens Industriais |
| Subsector | Material de Transporte |
| Segment | Material Aeronáutico e de Defesa |
| Participation Indexes | GPTW, IBOVESPA, IBRA, IBRX, IBRX50, ICO2, IGC, IGCT, IGNM, INDX, ITAG, IVBX, MLCX |
| Updated 11/21/2024 | |
Relative Prices - EMBR3
| Price/Earnings | 15.51 |
| Price/SBV | 2.36 |
| Price/Net Sales | 1.28 |
| Price/CFO | 12.46 |
| Price/FCF | 21.10 |
| Price/Total Assets | 0.63 |
| Price/EBIT | 12.39 |
| Price/Working Capital | 3.18 |
| Price/NCAV | -1.19 |
| EV/EBIT | 15.43 |
| EV/EBITDA | 10.99 |
| EV/Net Sales | 1.60 |
| EV/CFO | 15.52 |
| EV/FCF | 26.28 |
| EV/Total Assets | 0.79 |
| Company Market Cap | R$ 40.31 B |
| Enterprise Value | R$ 50.20 B |
| Current Financial Statement Date | 09/30/2024 |
| Current Share Price | R$ 54.44 |
| Share Price Date | 11/19/2024 |
| Dividend Yield | 0.00% |
| Updated 11/21/2024 | |
Income Statement - EMBR3
| Net Revenue | R$ 31.41 B |
| Gross Result | R$ 5.51 B |
| EBIT | R$ 3.25 B |
| Depreciation and Amortization | - R$ 1.31 B |
| EBITDA | R$ 4.57 B |
| Net Profit | R$ 2.60 B |
| Net Profit/Share | R$ 3.51 |
| Updated 11/08/2024 | |
| Net Revenue | R$ 9.39 B |
| Gross Result | R$ 1.75 B |
| EBIT | R$ 1.58 B |
| Depreciation and Amortization | - R$ 375.14 M |
| EBITDA | R$ 1.96 B |
| Net Profit | R$ 991.49 M |
| Profit/Share | R$ 1.34 |
| Updated 11/08/2024 | |
Price and Volume Behavior - EMBR3
| Lowest Price 52 weeks | R$ 19.72 |
| Highest Price 52 weeks | R$ 56.69 |
| Variation 2024 | 147.23% |
| Variation 1 year | 172.61% |
| Variation 2 years(total) | 283.38% |
| Variation 2 years(yearly) | 95.44% |
| Variation 3 years(total) | 162.74% |
| Variation 3 years(yearly) | 37.95% |
| Variation 4 years(total) | 589.11% |
| Variation 4 years(yearly) | 62.02% |
| Variation 5 years(total) | 212.87% |
| Variation 5 years(yearly) | 25.59% |
| Average Daily Volume (3 months) | R$ 336.13 M |
| Updated 11/21/2024 | |
Returns and Margins - EMBR3
| Return on Initial Tangible Capital | 11.87% |
| Return on Initial Invested Capital | 9.79% |
| Pre-Tax Return on Initial Tangible Capital | 17.98% |
| Pre-Tax Return on Initial Invested Capital | 14.83% |
| Return on Initial Shareholder´s Equity | 20.37% |
| Return on Initial Asset | 4.98% |
| Gross Margin | 17.54% |
| Net Margin | 8.27% |
| EBIT Margin | 10.36% |
| EBITDA Margin | 14.54% |
| Initial Asset Turnover | 0.60 |
| Financial Leverage | 3.72 |
| Liabilities/Net Worth | 2.72 |
| Net Debt/EBITDA | 2.17 |
| Updated 11/08/2024 | |
Balance Sheet - EMBR3
| Cash and Cash Equivalents | R$ 4.53 B |
| Total Assets | R$ 63.59 B |
| Short-Term Debt | R$ 552.87 M |
| Long-Term Debt | R$ 13.86 B |
| Gross Debt | R$ 14.42 B |
| Net Debt | R$ 9.89 B |
| Shareholder´s Equity | R$ 17.07 B |
| Share Book Value | R$ 23.06 |
| Common Shares | 740,465,000 |
| Preferred Shares | 0 |
| Total | 740,465,000 |
| Common Shares in Treasury | 5,832,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 5,832,000 |
| Common Shares (Except Treasury) | 734,633,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 734,633,000 |
| Updated 11/08/2024 | |
Cash Flow - EMBR3
| Operating Cash Flow | R$ 3.23 B |
| Cash Flow from Investments | - R$ 3.27 B |
| Financing Cash Flow | - R$ 886.72 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 632.63 M |
| Updated 11/08/2024 | |
| Operating Cash Flow | R$ 952.84 M |
| Cash Flow from Investments | - R$ 704.55 M |
| Financing Cash Flow | R$ 375.16 M |
| Increase (Reduction) in Cash and Equivalents | R$ 511.48 M |
| Updated 11/08/2024 | |
Experimental - EMBR3
| CAPEX 3 months | - R$ 379.56 M |
| Free Cash Flow 3 months | R$ 573.28 M |
| CAPEX 12 months | - R$ 1.32 B |
| Free Cash Flow 12 months | R$ 1.91 B |
| Updated 11/08/2024 | |